New Zealand Company on Track to Market Algal EPA

Photonz Corp. (Auckland, New Zealand) has announced the successful transfer of its proprietary omega-3 EPA to a contract facility in Canada where it can then be manufactured on an industrial level.

Earlier this year, the company announced that it would soon enter the burgeoning omega-3 market with EPA derived from a proprietary strain of microalgae. The company has since transferred, duplicated, and scaled up its algae culture at a Canadian facility, ultimately producing around 20 tons of its fermented final product.

“As a result of the success of this project I have confirmed to our investors that we remain on track to manufacture, in 2012, an industrial scale end-product that addresses a massive opportunity in the $60 billion cardiovascular disease market,” said Photonz chief executive Greg Moss-Smith.